Genes, Vol. 14, Pages 953: Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries

Genes, Vol. 14, Pages 953: Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries

Genes doi: 10.3390/genes14050953

Authors: Lyudmila V. Dergunova Ivan B. Filippenkov Svetlana A. Limborska Nikolay F. Myasoedov

Ischemic stroke continues to be one of the leading causes of death and disability in the adult population worldwide. The currently used pharmacological methods for the treatment of ischemic stroke are not effective enough and require the search for new tools and approaches to identify therapeutic targets and potential neuroprotectors. Today, in the development of neuroprotective drugs for the treatment of stroke, special attention is paid to peptides. Namely, peptide action is aimed at blocking the cascade of pathological processes caused by a decrease in blood flow to the brain tissues. Different groups of peptides have therapeutic potential in ischemia. Among them are small interfering peptides that block protein–protein interactions, cationic arginine-rich peptides with a combination of various neuroprotective properties, shuttle peptides that ensure the permeability of neuroprotectors through the blood–brain barrier, and synthetic peptides that mimic natural regulatory peptides and hormones. In this review, we consider the latest achievements and trends in the development of new biologically active peptides, as well as the role of transcriptomic analysis in identifying the molecular mechanisms of action of potential drugs aimed at the treatment of ischemic stroke.